Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serge Y Fuchs

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Biorxiv : the Preprint Server for Biology|April 10, 2026
SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapiesQuoc Thang Bui, Raghavendra Basavaraja, Mayura R Dhamdhere, et al.
Nature Cancer|May 31, 2022
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumorsHongru Zhang, Pengfei Yu, Vivek S Tomar, et al.
Cancer Cell|January 16, 2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular VesiclesAngelica Ortiz, Jun Gui, Farima Zahedi, et al.
Science Translational Medicine|September 15, 2021
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical modelsEric S Lightcap, Pengfei Yu, Stephen Grossman, et al.
Science Translational Medicine|August 21, 2024
Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapiesZhen Lu, Ioannis Verginadis, Motofumi Kumazoe, et al.
Nature Cell Biology|June 2, 2022
A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progressionIoannis I Verginadis, Harris Avgousti, James Monslow, et al.
Biorxiv : the Preprint Server for Biology|September 25, 2023
Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6)Charline Ogier, Akino Mercy Charles Solomon, Zhen Lu, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Biorxiv : the Preprint Server for Biology|April 10, 2026
SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapiesQuoc Thang Bui, Raghavendra Basavaraja, Mayura R Dhamdhere, et al.
Nature Cancer|May 31, 2022
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumorsHongru Zhang, Pengfei Yu, Vivek S Tomar, et al.
Cancer Cell|January 16, 2019
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular VesiclesAngelica Ortiz, Jun Gui, Farima Zahedi, et al.
Science Translational Medicine|September 15, 2021
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical modelsEric S Lightcap, Pengfei Yu, Stephen Grossman, et al.
Science Translational Medicine|August 21, 2024
Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapiesZhen Lu, Ioannis Verginadis, Motofumi Kumazoe, et al.
Nature Cell Biology|June 2, 2022
A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progressionIoannis I Verginadis, Harris Avgousti, James Monslow, et al.
Biorxiv : the Preprint Server for Biology|September 25, 2023
Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6)Charline Ogier, Akino Mercy Charles Solomon, Zhen Lu, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Pageof 12